Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Richmond CEO Presents Landmark Data on Repeat-Dose Gene Editing

9
September 2024

Richmond CEO Presents Landmark Data on Repeat-Dose Gene Editing

View Articles

Richmond promotes new Director of Communications and Participant Engagement

12
August 2024

Richmond Pharmacology is delighted to announce the promotion of Liz Romano to the new position of Director of Communications and Participant Engagement.

View Articles

Richmond Chief Medical Director calls for a ‘toolbox’ of standards and guidelines for clinical trials

5
August 2024

The British Journal of Clinical Pharmacology has published an editorial by Richmond’s Dr Ulrike Lorch and Professor Charles Vincent of Oxford University calling for a ‘toolbox’ of practical standards and guidelines for early phase clinical trials.

View Articles

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

27
June 2024

Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.

View Articles

A first of a kind trial in the fight against malaria

12
June 2024

Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.

View Articles

Patient with rare bleeding disorder becomes first to test new treatment

22
May 2024

The thousands of patients who participate in Richmond’s trials are helping to advance medical science and save lives and, in the process, some make history. In a film released today, one trial participant tells her story.

View Articles

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event